Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625515 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
A Phase 1 study, sponsored by Accent Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT06625515 is a Phase 1 study that was terminated before completion, run by Accent Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT06625515, a Phase 1 study, was terminated before completion, sponsored by Accent Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-559 in patients with advanced solid tumors and molecularly defined cancers.
Interventions
- DRUG ATX-559
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625515
The ClinicalTrials.gov registry entry for NCT06625515 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accent Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATX-559 is the first listed.
NCT06625515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06625515 about?
NCT06625515 is a clinical study titled "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers". The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-559 in patients with advanced solid tumors and molecularly defined...
What is the current status of trial NCT06625515?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2024-10-11. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06625515?
The interventions under investigation include: ATX-559 (DRUG).
Who is sponsoring clinical trial NCT06625515?
This trial is sponsored by Accent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.